NK cells and ILCs in tumor immunotherapy.
Sivori S, Pende D, Quatrini L, Pietra G, Della Chiesa M, Vacca P, Tumino N, Moretta F, Mingari MC, Locatelli F, Moretta L.
Mol Aspects Med. 2021 Aug;80:100870. doi: 10.1016/j.mam.2020.100870. Epub 2020 Aug 13.
Natural killer-cell neoplasms.
Greer JP, Mosse CA.
Curr Hematol Malig Rep. 2009 Oct;4(4):245-52. doi: 10.1007/s11899-009-0032-3.
Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.
Nishimura A, Yokoyama K, Naruto T, Yamagishi C, Imamura T, Nakazono H, Kimura S, Ito M, Sagisaka M, Tanaka Y, Piao J, Namikawa Y, Yanagimachi M, Isoda T, Kanai A, Matsui H, Isobe T, Sato-Otsubo A, Higuchi N, Takada A, Okuno H, Saito S, Karakawa S, Kobayashi S, Hasegawa D, Fujisaki H, Hasegawa D, Koike K, Koike T, Rai S, Umeda K, Sano H, Sekinaka Y, Ogawa A, Kinoshita A, Shiba N, Miki M, Kimura F, Nakayama H, Nakazawa Y, Taga T, Taki T, Adachi S, Manabe A, Koh K, Ishida Y, Takita J, Ishikawa F, Goto H, Morio T, Mizutani S, Tojo A, Takagi M.
Sci Adv. 2023 Dec 15;9(50):eadj4407. doi: 10.1126/sciadv.adj4407. Epub 2023 Dec 13.
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Sanchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, Casado JG, Morgado S, Duran E, Solana R, Tarazona R.
Cancer Immunol Immunother. 2016 Apr;65(4):453-63. doi: 10.1007/s00262-015-1720-6. Epub 2015 Jun 10.
Natural killer cells.
Kay NE.
Crit Rev Clin Lab Sci. 1986;22(4):343-59. doi: 10.3109/10408368509165790.
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia.
Wang Y, Huang B, Liang T, Jiang L, Wu M, Liu X, Zhu M, Song X, Zhao N, Wei H, Zheng C, Ni F.
Cell Rep Med. 2024 Jun 18;5(6):101580. doi: 10.1016/j.xcrm.2024.101580. Epub 2024 May 21.
Natural killer cell-triggering receptors in patients with acute leukaemia.
Fauriat C, Marcenaro E, Sivori S, Rey J, Gastaut JA, Moretta A, Olive D, Costello RT.
Leuk Lymphoma. 2003 Oct;44(10):1683-9. doi: 10.1080/1042819031000104006.
SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.
Chang YH, Yamamoto K, Fujino T, Wang TW, Sugimoto E, Zhang W, Yabushita T, Suzaki K, Pietsch EC, Weir BA, Crescenzo R, Cowley GS, Attar R, Philippar U, Wunderlich M, Mizukawa B, Zheng Y, Enomoto Y, Imai Y, Kitamura T, Goyama S.
Cell Rep. 2024 Aug 27;43(8):114536. doi: 10.1016/j.celrep.2024.114536. Epub 2024 Aug 2.
Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J, Niu T.
J Hematol Oncol. 2020 Dec 7;13(1):167. doi: 10.1186/s13045-020-00996-x.
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Arellano-Ballestero H, Sabry M, Lowdell MW.
Cells. 2023 Feb 16;12(4):633. doi: 10.3390/cells12040633.
